Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Bimatoprost is a synthetic prostamide related to dinoprost (prostaglandin F2α). It is used to reduce intraocular pressure in the treatment of glaucoma and in the treatment of hypotrichosis of the eyelashes. It is administered as eye drops once a day at night.
At the date of the last update, we found no published data on its excretion in breast milk.
The small dose and low plasma absorption of most topical ophthalmic preparations make it unlikely that significant amounts will pass into breast milk, so its use as ophthalmic eye drops would have a very low risk during breastfeeding.
In addition, its short half-life, high plasma protein binding and large volume of distribution make it even more unlikely to pass into breast milk.
Systemic absorption should be minimized by pressing the tear duct (inner corner of the eye) with the finger for 1 to 2 minutes and administering the dose immediately after breastfeeding. (Belkin 2020, Blumen 2020, Méndez 2012)